DE3941873A1 - Hollow fibres coated which cells with inhibit coagulation - for long-term use as implants in arteries and veins to carry sensors - Google Patents

Hollow fibres coated which cells with inhibit coagulation - for long-term use as implants in arteries and veins to carry sensors

Info

Publication number
DE3941873A1
DE3941873A1 DE3941873A DE3941873A DE3941873A1 DE 3941873 A1 DE3941873 A1 DE 3941873A1 DE 3941873 A DE3941873 A DE 3941873A DE 3941873 A DE3941873 A DE 3941873A DE 3941873 A1 DE3941873 A1 DE 3941873A1
Authority
DE
Germany
Prior art keywords
cells
arteries
veins
implants
hollow fibres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE3941873A
Other languages
German (de)
Inventor
Jakob Dr Bodziony
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bodziony Jakob Dr 66117 Saarbruecken De
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE3941873A priority Critical patent/DE3941873A1/en
Publication of DE3941873A1 publication Critical patent/DE3941873A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0077Special surfaces of prostheses, e.g. for improving ingrowth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/005Ingredients of undetermined constitution or reaction products thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A semi-permeable material consisting of a hollow fibre is coated with a layer of firmly adhering cells which can control and stop coagulation processes by e.g. secreting certain factors, and which are pref. endo- and meso thelial cells, or cells which can change into such cells and which are immunologically tolerated like the cells of the host. USE/ADVANTAGE - The semi-permeable material can be used as an implant in arteries and veins for several years. The hollow fibres can be easily transported and implanted in the vascular system and can also be fitted with suitable sensors e.g. to monitor intravascular O2 or to regulate blood sugar levels in diabetics.

Description

Gattung des AnmeldungsgegenstandesGenre of the object of registration

Die Erfindung betrifft semipermeables Material, am häufigsten in der Form einer Hohlfaser gestaltet und beschichtet mit fest angehefteten Zellen, die die Gerinnungsprozesse durch u. a. Sekretion von bestimmten Faktoren kontrollieren und aufhalten können (vor allem Endo- und Mesothelialzellen aber auch Zellen die sich in solche umwandeln können) und immunologisch wie eigene Zellen toleriert sind, was mehrjährige Implantation in Arterien und Venen ermöglicht.The invention relates to semi-permeable material, most often in the form a hollow fiber designed and coated with firmly attached cells, which the coagulation processes by u. a. Secretion of certain factors control and stop (especially endo- and mesothelial cells but also cells that can transform into such) and immunologically like own cells are tolerated, resulting in perennial implantation in arteries and Allows veins.

Angaben zur GattungInformation on the genus

Die vorgegebene beschichtete Hohlfaser soll vor allem als ein Teil oder die Hülle der in das Gefäßsystem implantablen Sensoren, Biosensoren und ion­ selektiven Elektroden benutzt werden. Das kann die bisher nur zeitlich sehr begrenzt (1-2 Tage) realisierbare in-vivo Überwachung der lebenswichtigen metabolischen Faktoren wie pH, pO2, pCO2, Ca++, K⁺, Na⁺, Glukose, Harnstoff, Kreatinin usw. und deren automatische Korrektur in einem open-loop oder closed-loop System möglich machen. Die vorgegebene beschichtete Hohlfaser kann auch als mehrjährig-implantierte Infusionskanüle, als eine semipermeable Kammer für die ins Gefäßsystem implantierte Zellen und Geweben und als eine Diffusionskammer für bestimmte Arzneimittel benutzt werden.The specified coated hollow fiber is to be used above all as a part or the shell of the sensors, biosensors and ion-selective electrodes which are implantable in the vascular system. This can be done in vivo monitoring of the vital metabolic factors such as pH, pO 2 , pCO 2 , Ca ++ , K⁺, Na⁺, glucose, urea, creatinine etc. make their automatic correction possible in an open-loop or closed-loop system. The specified coated hollow fiber can also be used as a multi-year implanted infusion cannula, as a semipermeable chamber for the cells and tissues implanted in the vascular system and as a diffusion chamber for certain medicinal products.

Stand der TechnikState of the art

Bei bisherigen Versuchen zur Verhinderung der Aktivierung des Gerinnungs­ systems und der begleitenden Beschädigung der in das Gefäßsysstem implantier­ ten Sensoren (Armstrong und Mitarb., 1976; Goddard und Mitarb., 1974; Parce und Mitarb., 1989; Turner und Mitarb., 1987) hat man nur die Silikon- oder Teflonmembranen (Pfeiffer, 1987) und die Beschichtung von Sensoren mit hepa­ rinhaltigen Materialien (Hagihara und Mitarb., 1981) angewandt. In previous attempts to prevent the activation of coagulation systems and the accompanying damage to the implant in the vascular system ten sensors (Armstrong and co-workers, 1976; Goddard and co-workers, 1974; Parce and co-workers, 1989; Turner et al., 1987) you only have the silicone or Teflon membranes (Pfeiffer, 1987) and the coating of sensors with hepa materials containing (Hagihara and co-workers, 1981) applied.  

Kritik des Standes der TechnikCritique of the state of the art

Die Hauptursache des Mißerfolgs der zur in-vivo Überwachung verwendeten und in Gefäßsystem implantierten Sensoren ist die Präzipitation der Erthrozyten, Thrombozyten, Leukozyten und des Fibrins auf der Sensoroberfläche. Die Beschichtung des Sensors mit heparinhaltigen Materialien oder mit Silicon- und Teflonmembra­ nen verzögert nur die oben beschriebene Präzipitation aber es kann sie nicht verhindern (Pfeifer, 1987; Santiago und Mitarb., 1979; Hagihara und Mitarb., 1981). Im besten Fall muß der Sensor oder die Membran alle 24 Stunden gewechselt werden. Das macht die langzeitige Implantation von solchen Sensoren unmöglich und es ist u. a. eines der wesentlichsten Probleme bei der Konstruk­ tion des Systems zur automatischen Regulation des Blutzuckers bei diabetischen Patienten (Pfeiffer, 1987; Santiago und Mitarb., 1979).The main cause of failure of and used for in vivo monitoring sensors implanted in vascular system is the precipitation of erythrocytes, Platelets, leukocytes and fibrin on the sensor surface. The coating of the sensor with heparin-containing materials or with silicone and Teflon membrane NEN only delays the precipitation described above but it cannot prevent (Pfeifer, 1987; Santiago and coworkers, 1979; Hagihara and coworkers., 1981). In the best case, the sensor or membrane must be replaced every 24 hours change. This makes the long-term implantation of such sensors impossible and it is u. a. one of the most important problems in the construction tion of the system for the automatic regulation of blood sugar in diabetic Patients (Pfeiffer, 1987; Santiago and co-workers, 1979).

Aufgabetask

Die Konstruktion der Hülle für implantable Sensoren und andere Materialien, die einerseits den Kontakt des Sensors mit dem Blutultrafiltrat, dessen bio­ chemische Zusammensetzung in bestimmten, sehr kleinen Zeitabständen die Zusam­ mensetzung des Blutes (ohne morphotische Elemente und bestimmte Proteine, die größer als die Permeablitätsgrenze sind) wiederspiegelt, andererseits die mehrjährige Implantation in Arterien und Venen ermöglicht.The design of the case for implantable sensors and other materials, on the one hand the contact of the sensor with the blood ultrafiltrate, the bio chemical composition in certain, very small time intervals blood composition (without morphotic elements and certain proteins, which are greater than the permeability limit), on the other hand allows for several years of implantation in arteries and veins.

Lösungsolution

Diese Aufgabe wird erfindungsmäßig dadurch gelöst, daß semipermeables Material mit entsprechend poröser und aktivierter Oberfläche mit fest angehefteten Zellen, die die Gerinnugsprozesse kontrollieren und aufhalten können und immunologisch wie eigene Zellen toleriert sind, beschichtet worden ist.This object is achieved according to the invention in that semipermeable material with a correspondingly porous and activated surface with firmly attached Cells that can control and stop the coagulation processes and immunologically how own cells are tolerated, has been coated.

Erzielbare VorteileAchievable advantages

Der Gegenstand der Erfindung ist gewerblich anwendbar durch die Herstellung von semipermeablen Materialien in Gestalt von z. B. Hohlfasern, die vor allem mit autogenen oder gewebetypisierten und gewebekulturproduzierten allogenen Endo- und Mesothelialzellen beschichtet sind. Diese Hohlfasern können einfach transportiert und in das Gefäßsystem implantiert werden. Die zellbeschichteten Hohlfasern können z. B. auch zusammen mit eingebauten Sensoren hergestellt und in implantationsfertiger Form transportiert werden. The object of the invention is industrially applicable through the production of semipermeable materials in the form of e.g. B. hollow fibers, especially with autogenous or tissue-typed and tissue culture-produced allogeneic Endo- and mesothelial cells are coated. These hollow fibers can be simple transported and implanted in the vascular system. The cell-coated Hollow fibers can e.g. B. also produced together with built-in sensors and transported in a form ready for implantation.  

Beschreibung des AusführungsbeispielsDescription of the embodiment

Abb. 1 und 2 zeigen das semipermeable Material in Gestalt einer Hohlfaser, mit eine Permeabilitätsgrenze von 50 kD, beschichtet in vitro mit autogenen Endothelialzellen, die aus der Jugularvene isoliert und durch Gewebekultur­ technik vermehrt worden sind. Die Hohlfaser war danach in die untere Hohlvene der Ratte auf die Dauer von einem Jahr implantiert worden (Abb. 1, 2). Es wurde in einer Reihe von ähnlichen Versuchen festgestellt, daß die vorgegebe­ nen beschichteten Hohlfasern keine Aktivierung des Gerinnungssystem induzier­ ten und auch nie immunologisch oder biologisch als Fremdkörper erkannt wurden. Die biochemische Zusammensetzung des Blutultrafiltrats in inneren Teil der Hohlfaser spiegelt genau die biochemische Zusammensetzung des Blutes wieder (ohne Moleküle die großer als 50 kD sind). Eine pH und pO2-Mikroelektrode, die im inneren Teil der Hohlfaser installiert und mit einem Meßsystem verbun­ den war, konnte sehr genau und langzeitig die pH oder pO2-Werte messen. Fig. 1 and 2 show the semipermeable material in the form of a hollow fiber, with a permeability limit of 50 kD, coated in vitro with autogenous endothelial cells that have been isolated from the jugular vein and have been multiplied by tissue culture technology. The hollow fiber was then implanted in the rat's inferior vena cava for a period of one year ( Fig. 1, 2). It was found in a series of similar experiments that the predetermined coated hollow fibers did not induce activation of the coagulation system and were never recognized as foreign matter immunologically or biologically. The biochemical composition of the blood ultrafiltrate in the inner part of the hollow fiber exactly reflects the biochemical composition of the blood (without molecules larger than 50 kD). A pH and pO 2 microelectrode, which was installed in the inner part of the hollow fiber and connected to a measuring system, was able to measure the pH or pO 2 values very precisely and over the long term.

FundstellenSites

1. Armstrong R.F., Hutchinson J.M., Lincoln C., lngram D., Soutter L.: Conti­ nous mesurement of arterial oxygen tension during one-lung anaesthesia. Bri­ tish Journal of Anaesthesiology, 48, 1005-1010, 1976.
2. Goddard P., Keith J., Marcovitch H., Roberton N.R.C., Rolfe P., Scopes J.W.: Use of a continously recording intravascular oxygen electrode in the newborn. Archives of Disease in Childhood, 49, 853-860, 1974.
3. Hagihara B., Ishibashi F., Sato N., Minami T., Okada Y., Sugimoto T.: Intravascular oxygen monitoring with a polarographic oxygen cathode. Journal of Biomedical Engineering, 3/1, 9-16, 1981.
4. Parce W.J., Owicki J.C., Kerco K.M., Sigal G.B., Wada H.G., Muir V.C., Bousse L.J., Ross K.L., Sikic B.J., MCConnel H.M.: Detection of cell-affecting agents with a silicon biosensor. Scince, 246, 243-247, 1989.
5. Pfeiffer E.F.: On the way to the automated (blood) glucose regulation in diabetes: the dark past, the grey present and the rose future. Diabetolo­ gia, 30, 51-65, 1987.
6. Santiago J.V., Clemens A.H., Clarke W.L., Kipnis D.M.: Closed-loop and open-loop devices for blood glucose control in normal and diabetic subjects. Diabetes, 28/1, 71-84, 1979.
7. Turner A.P.F., Karube J., Wilson G.S. (eds.): Biosensors. Fundamentals and applications. Oxford Univ. Press, 1987, ISBN 0-19-854724-2.
1. Armstrong RF, Hutchinson JM, Lincoln C., Ingram D., Soutter L .: Conti nous mesurement of arterial oxygen tension during one-lung anesthesia. British Journal of Anaesthesiology, 48, 1005-1010, 1976.
2. Goddard P., Keith J., Marcovitch H., Roberton NRC, Rolfe P., Scopes JW: Use of a continously recording intravascular oxygen electrode in the newborn. Archives of Disease in Childhood, 49, 853-860, 1974.
3. Hagihara B., Ishibashi F., Sato N., Minami T., Okada Y., Sugimoto T .: Intravascular oxygen monitoring with a polarographic oxygen cathode. Journal of Biomedical Engineering, 3/1, 9-16, 1981.
4. Parce WJ, Owicki JC, Kerco KM, Sigal GB, Wada HG, Muir VC, Bousse LJ, Ross KL, Sikic BJ, MCConnel HM: Detection of cell-affecting agents with a silicon biosensor. Scince, 246, 243-247, 1989.
5. Pfeiffer EF: On the way to the automated (blood) glucose regulation in diabetes: the dark past, the gray present and the rose future. Diabetolo gia, 30, 51-65, 1987.
6. Santiago JV, Clemens AH, Clarke WL, Kipnis DM: Closed-loop and open-loop devices for blood glucose control in normal and diabetic subjects. Diabetes, 28/1, 71-84, 1979.
7. Turner APF, Karube J., Wilson GS (eds.): Biosensors. Fundamentals and applications. Oxford Univ. Press, 1987, ISBN 0-19-854724-2.

Claims (1)

Semipermeables Material, am häufigsten in der Form einer Hohlfaser gestaltet, gekennzeichnet durch die Beschichtung mit fest angehafteten Zellen, die die Gerinnungsprozesse durch u. a. Sekretion von bestimmten Faktoren kontrollieren und aufhalten können (vor allem Endo- und Mesothelialzellen aber auch Zellen die sich in solche umwandeln können) und immunologisch wie eigene Zellen toleriert sind, was mehrjährige Implantation in Arterien und Venen ermöglicht.Semipermeable material, most often designed in the form of a hollow fiber, characterized by the coating with firmly attached cells, which can control and stop the coagulation processes by, among other things, secretion of certain factors (especially endo- and mesothelial cells, but also cells that can convert into such ) and are tolerated immunologically like own cells, which enables implantation in arteries and veins of several years.
DE3941873A 1989-12-19 1989-12-19 Hollow fibres coated which cells with inhibit coagulation - for long-term use as implants in arteries and veins to carry sensors Withdrawn DE3941873A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE3941873A DE3941873A1 (en) 1989-12-19 1989-12-19 Hollow fibres coated which cells with inhibit coagulation - for long-term use as implants in arteries and veins to carry sensors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3941873A DE3941873A1 (en) 1989-12-19 1989-12-19 Hollow fibres coated which cells with inhibit coagulation - for long-term use as implants in arteries and veins to carry sensors

Publications (1)

Publication Number Publication Date
DE3941873A1 true DE3941873A1 (en) 1991-06-20

Family

ID=6395778

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3941873A Withdrawn DE3941873A1 (en) 1989-12-19 1989-12-19 Hollow fibres coated which cells with inhibit coagulation - for long-term use as implants in arteries and veins to carry sensors

Country Status (1)

Country Link
DE (1) DE3941873A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4123629A1 (en) * 1990-08-06 1992-02-20 Jakob Dr Bodziony Implantable semi-permeable bio-artificial organ - allowing biological signal and metabolic substance flow by pressure gradient
US5704910A (en) * 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
WO2002056796A1 (en) * 2000-12-01 2002-07-25 Nephros Therapeutics, Inc. Intravascular blood conditioning device and use thereof
FR2955179A1 (en) * 2010-01-13 2011-07-15 Univ Bordeaux 1 SENSOR FOR MEASURING INSULIN NEEDS OF A PATIENT AND METHOD FOR MANUFACTURING THE SAME
US8048419B2 (en) 2006-02-02 2011-11-01 Innovative Biotherapies, Inc. Extracorporeal cell-based therapeutic device and delivery system
US9029144B2 (en) 2008-06-18 2015-05-12 Innovative Bio Therapies, Inc. Methods for enhanced propagation of cells

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980002378A1 (en) * 1979-05-03 1980-11-13 Commw Scient Ind Res Org Device for promoting endothelial cell motility and/or vascularisation
DE3410631A1 (en) * 1983-03-23 1984-09-27 Ramot University Authority For Applied Research And Industrial Development Ltd., Tel Aviv IMPLANTATION MATERIAL FOR RESTORING DEFECTIVE CARTILAGE AND BONE
DE3432143A1 (en) * 1983-09-01 1985-03-21 Damon Biotech, Inc., Needham Heights, Mass. METHOD FOR ENCLOSURE A MATERIAL TO BE ENCLOSED
DE3422639C2 (en) * 1984-06-19 1986-07-10 Gebrüder Sulzer AG, Winterthur Glandular prosthesis
GB2185408A (en) * 1986-01-16 1987-07-22 Rhode Island Hospital Neovascularization
EP0259536A2 (en) * 1986-09-11 1988-03-16 BAXTER INTERNATIONAL INC. (a Delaware corporation) Biological implant with textured surface
DE3637260A1 (en) * 1986-11-03 1988-05-11 Max Planck Gesellschaft METHOD FOR POPULATING SURFACES WITH ENDOTHEL CELLS
EP0286284A1 (en) * 1987-03-30 1988-10-12 Brown University Research Foundation Semipermeable nerve guidance channels
EP0290642A1 (en) * 1987-05-12 1988-11-17 Mittermayer, Christian, Dr. med. Method for seeding polymeric surfaces with human endothelial cells
EP0296475A1 (en) * 1987-06-23 1988-12-28 Istituto Nazionale Per La Ricerca Sul Cancro Method for preserving transplantable sheets of epithelium cultured in vitro
EP0301777A1 (en) * 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
WO1989005345A1 (en) * 1987-12-11 1989-06-15 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
WO1989007425A2 (en) * 1988-02-17 1989-08-24 Genethics Limited Clinical developments using amniotic cells

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980002378A1 (en) * 1979-05-03 1980-11-13 Commw Scient Ind Res Org Device for promoting endothelial cell motility and/or vascularisation
DE3410631A1 (en) * 1983-03-23 1984-09-27 Ramot University Authority For Applied Research And Industrial Development Ltd., Tel Aviv IMPLANTATION MATERIAL FOR RESTORING DEFECTIVE CARTILAGE AND BONE
DE3432143A1 (en) * 1983-09-01 1985-03-21 Damon Biotech, Inc., Needham Heights, Mass. METHOD FOR ENCLOSURE A MATERIAL TO BE ENCLOSED
DE3422639C2 (en) * 1984-06-19 1986-07-10 Gebrüder Sulzer AG, Winterthur Glandular prosthesis
DE3701148C2 (en) * 1986-01-16 1989-08-31 Rhode Island Hospital, Providence, R.I., Us
GB2185408A (en) * 1986-01-16 1987-07-22 Rhode Island Hospital Neovascularization
EP0259536A2 (en) * 1986-09-11 1988-03-16 BAXTER INTERNATIONAL INC. (a Delaware corporation) Biological implant with textured surface
DE3637260A1 (en) * 1986-11-03 1988-05-11 Max Planck Gesellschaft METHOD FOR POPULATING SURFACES WITH ENDOTHEL CELLS
EP0286284A1 (en) * 1987-03-30 1988-10-12 Brown University Research Foundation Semipermeable nerve guidance channels
EP0290642A1 (en) * 1987-05-12 1988-11-17 Mittermayer, Christian, Dr. med. Method for seeding polymeric surfaces with human endothelial cells
EP0296475A1 (en) * 1987-06-23 1988-12-28 Istituto Nazionale Per La Ricerca Sul Cancro Method for preserving transplantable sheets of epithelium cultured in vitro
EP0301777A1 (en) * 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
WO1989005345A1 (en) * 1987-12-11 1989-06-15 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
WO1989007425A2 (en) * 1988-02-17 1989-08-24 Genethics Limited Clinical developments using amniotic cells
EP0333328A2 (en) * 1988-02-17 1989-09-20 Genethics Limited Clinical developments using amniotic cells

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4123629A1 (en) * 1990-08-06 1992-02-20 Jakob Dr Bodziony Implantable semi-permeable bio-artificial organ - allowing biological signal and metabolic substance flow by pressure gradient
US5704910A (en) * 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US5911704A (en) * 1995-06-05 1999-06-15 Nephros Therapeutics, Inc. Implantable device and uses therefor
US6572605B1 (en) 1995-06-05 2003-06-03 Nephros Therapeutics, Inc. Implantable device and use therefor
US6716208B2 (en) 1995-06-05 2004-04-06 Nephros Therapeutics, Inc. Implantable device and use therefor
WO2002056796A1 (en) * 2000-12-01 2002-07-25 Nephros Therapeutics, Inc. Intravascular blood conditioning device and use thereof
US8048419B2 (en) 2006-02-02 2011-11-01 Innovative Biotherapies, Inc. Extracorporeal cell-based therapeutic device and delivery system
US9029144B2 (en) 2008-06-18 2015-05-12 Innovative Bio Therapies, Inc. Methods for enhanced propagation of cells
WO2011086105A1 (en) * 2010-01-13 2011-07-21 Universite De Bordeaux 1 Sensor for measuring the activity of beta-pancreatic cells or of islets of langerhans, manufacture and use of such a sensor
FR2955179A1 (en) * 2010-01-13 2011-07-15 Univ Bordeaux 1 SENSOR FOR MEASURING INSULIN NEEDS OF A PATIENT AND METHOD FOR MANUFACTURING THE SAME
AU2011206641B2 (en) * 2010-01-13 2016-06-09 Centre National De La Recherche Scientifique Sensor for measuring the activity of beta-pancreatic cells or of islets of Langerhans, manufacture and use of such a sensor
AU2011206641A8 (en) * 2010-01-13 2016-07-07 Centre National De La Recherche Scientifique Sensor for measuring the activity of beta-pancreatic cells or of islets of Langerhans, manufacture and use of such a sensor
US9962113B2 (en) 2010-01-13 2018-05-08 Universite De Bordeaux 1 Sensor for measuring the activity of beta-pancreatic cells or of islets of langerhans, manufacture and use of such a sensor

Similar Documents

Publication Publication Date Title
US5322063A (en) Hydrophilic polyurethane membranes for electrochemical glucose sensors
DE69322968T2 (en) Method and device for continuously monitoring an anolyte level
DE3850972T2 (en) PROCESS AND SYSTEM AND MEASURING CELL ARRANGEMENT FOR THE DETERMINATION OF GLUCOSE.
US10449270B2 (en) Collagen scaffolds, medical implants with same and methods of use
Sakakida et al. Ferrocene-mediated needle-type glucose sensor covered with newly designed biocompatible membrane
Fischer et al. Assessment of subcutaneous glucose concentration: validation of the wick technique as a reference for implanted electrochemical sensors in normal and diabetic dogs
DE2817363C2 (en) Method for determining the concentration of sugar and a suitable electrocatalytic sugar sensor
Wisniewski et al. Characterization of implantable biosensor membrane biofouling
DE69723689T2 (en) ELECTROCHEMICAL BIOSENSORS
DE69622700T2 (en) HOMOGENEOUS POLYMER COMPOSITIONS CONTAINING SILICONE FOR BIOSENSOR MEMBRANES
Wisniewski et al. Decreased analyte transport through implanted membranes: differentiation of biofouling from tissue effects
DE69837709T2 (en) DEVICE AND METHOD FOR DETERMINING THE ANALYTICAL LEVEL
Wisniewski et al. Methods for reducing biosensor membrane biofouling
DE60037592T2 (en) Method for measuring an analyte with the aid of an electrochemical biosensor, which can be switched off by applying a potential
EP0455072B1 (en) Silver chloride reference electrode
DE10020352A1 (en) Implantable blood glucose meter
DE3941873A1 (en) Hollow fibres coated which cells with inhibit coagulation - for long-term use as implants in arteries and veins to carry sensors
DE3422639C2 (en) Glandular prosthesis
DE4426694C2 (en) Device for long-term determination of the content of at least one substance in body fluids
DE69904293T2 (en) COMPOSITIONS AND METHODS FOR BIO-COMPATIBLE IMPLANTS
EP2452624A1 (en) Implantable theranostic article
DE19507107C1 (en) Implantable sensor system for determining substance concentrations in living organisms
Reach et al. BIOMED concerted action chemical sensors for in vivo monitoring. The biocompatibility issue
DE4011100A1 (en) Extracorporeal or implantable artificial organs - esp. to replace kidney or liver function, with semipermeable membrane controlled by biological and metabolic substances
DE4123629A1 (en) Implantable semi-permeable bio-artificial organ - allowing biological signal and metabolic substance flow by pressure gradient

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
8127 New person/name/address of the applicant

Owner name: BODZIONY, JAKOB, DR., 6650 HOMBURG, DE

8127 New person/name/address of the applicant

Owner name: BODZIONY, JAKOB, DR., 66117 SAARBRUECKEN, DE

8141 Disposal/no request for examination
8110 Request for examination paragraph 44
8170 Reinstatement of the former position
8139 Disposal/non-payment of the annual fee
8170 Reinstatement of the former position
8139 Disposal/non-payment of the annual fee